Lv52
850 积分 2022-06-02 加入
Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial
44分钟前
已完结
Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial
16小时前
已完结
Targeted activation of ferroptosis in colorectal cancer via LGR4 targeting overcomes acquired drug resistance
11天前
已完结
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
13天前
已完结
Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial
14天前
已完结
Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial
14天前
已完结
Statistical methods for handling missing data to align with treatment policy strategy
20天前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
1个月前
已完结
肿瘤免疫治疗疗效评价标准——iRECIST解读
1个月前
已完结
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial
2个月前
已关闭
皖公网安备34019202002308
